Skip to content

Transcutaneous auricular vagus nerve stimulation for improving moderate-to-severe sleep disturbance after orthognathic surgery: a randomized, double-blind, placebo-controlled clinical trial.

Transcutaneous auricular vagus nerve stimulation for improving moderate-to-severe sleep disturbance after orthognathic surgery: a randomized, double-blind, placebo-controlled clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127176
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-severe postoperative sleep disturbance

Interventions

The TaVNS group:Transcutaneous auricular vagus nerve stimulation (taVNS) : pulse width 250µs, frequency 30Hz, duty cycle 50%, duration 30min, and stimulation intensity set to the maximum current toler
The control group:Sham transcutaneous auricular vagus nerve stimulation (Sham taVNS): pulse width 250µs, frequency 30Hz, duty cycle 50%, duration 30min, electrical output was limited to an initial 30s

Sponsors

The Third Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, either sex, with BMI < 30 kg/m²; 2. ASA level I or II; 3. Scheduled to undergo orthognathic surgery under general anesthesia; 4. Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pre-existing sleep disturbance (Pittsburgh Sleep Quality Index [PSQI] score > 7), restless legs syndrome, or other relevant conditions; 2. Incompatibility of the auricular concha with the stimulator device, or presence of local skin lesions in the auricular region; 3. Recent or long-term use of cholinergic or anticholinergic medications; 4. Anticipated postoperative admission to the intensive care unit (ICU); 5. Presence of sick sinus syndrome, sinus bradycardia (heart rate < 50 beats/min), second-degree or higher atrioventricular block, or implantation of a cardiac pacemaker, cochlear implant, or other electronic devices; 6. Inability to communicate or cooperate preoperatively due to mental or language impairment; 7. Concurrent participation in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Incidence of moderate to severe sleep disorders on the first postoperative night;

Secondary

MeasureTime frame
Incidence of moderate to severe sleep disorders on the second postoperative night;Sleep quality on the first postoperative night;Sleep quality on the second postoperative night;postoperative wound pain;postoperative sore throat;postoperative nausea and vomiting;

Countries

China

Contacts

Public ContactZhang Xiao

The Third Affiliated Hospital of Air Force Medical University

zhangxiao2020130@163.com+86 187 1050 3976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026